Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 84Neoplasm Metastasis 8Neoplasms 6Sarcoma 4Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Untreated Operable Early Breast Cancer 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Somatostatinoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Estrogen Receptor-positive Breast Cancer × palbociclib × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡